FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics, Inc. (FATE) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (D+). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.8) | C (2.3) | D+ (1.7) | C+ (2.6) | C+ (2.6) | C (2.4) |
| 2026-11-04 | C+ (2.8) | C- (1.9) | D+ (1.6) | B- (2.9) | C+ (2.7) | C (2.4) |
| 2026-10-28 | C+ (2.8) | D+ (1.8) | D+ (1.7) | B (3.5) | C+ (2.7) | C (2.5) |
| 2026-10-21 | C+ (2.8) | D+ (1.8) | D+ (1.7) | B (3.4) | C+ (2.6) | C (2.5) |
| 2026-10-14 | C+ (2.8) | D+ (1.8) | D+ (1.7) | B- (3.0) | C+ (2.6) | C (2.4) |